NASDAQ:CGEM | Free Cash Flow | Cullinan Therapeutics, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2020-03-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$46.05M
2025-12-31-$38.11M$11,000.00-$38.12M
2025-03-31-$43.16M
2024-12-31-$36.63M$0.00-$36.63M
2024-03-31-$38.25M$0.00-$38.25M
2023-12-31-$18.13M$0.00-$18.13M
2023-03-31-$51M$159,000.00-$51.16M
2022-12-31-$24.98M$882,000.00-$25.87M
2022-03-31-$21.91M$0.00-$21.91M
2021-12-31-$15.17M$0.00-$15.17M
2021-03-31-$1.52M
2020-12-31-$9.44M-$1,000.00-$9.44M
2020-03-31-$5.02M$3,000.00-$5.02M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$175.75M$49,000.00-$175.8M
2024-12-31-$145.3M$0.00-$145.3M
2023-12-31-$134.28M$208,000.00-$134.48M
2022-12-31-$126.66M$1.13M-$127.8M-114.91%
2021-12-31-$43.43M$0.00-$43.43M
2020-12-31-$29.77M$10,000.00-$29.78M